Study 8541 had 3 treatment arms, study 9344 had a 3 × 2 factorial design, and study 9741 had a 2 × 2 factorial design.
Cumulative at-risk sample sizes over time are shown in each panel. The initial sample sizes were approximately equally divided among the groups in question. The dose effect of doxorubicin in study 9344 and the comparison of sequential or concurrent therapy in study 9741 are not shown; neither factor was associated with disease-free survival in unadjusted or adjusted analyses, nor were there significant differences within ER subgroups.
Risk was calculated as the number of events during the year divided by the number of patients at risk for experiencing the event at the beginning of the year. Cumulative at-risk sample sizes over time are shown in the respective panels of Figure 2. In the rightmost parts of the curves, the samples were relatively small and the SEs (not shown) were correspondingly large. Not all patients have reached the later follow-up times. In addition, patients with earlier recurrences have been eliminated from the at-risk group.
The left panels show the risks for patients not receiving tamoxifen (initial n = 552), and the right panels show the risks for patients receiving tamoxifen (same as Figure 3) (initial n = 472).
CAF indicates cyclophosphamide, doxorubicin (Adriamycin), and fluorouracil; ER, estrogen-receptor. Patients have mean tumor size, number of positive lymph nodes, and menopausal status as in the low-dose arm of study 8541. The modeled every 2-week regimen in study 9741 curves do not apply to the patients in study 9741 but instead for patients having the characteristics of the low-dose arm of study 8541. Study 8541 disease-free survival and study 9344 overall survival show an average reduction in hazard of 55% for ER-negative disease while they show average reductions of 26% and 23% for ER-positive disease receiving tamoxifen (see Table 2). The proportional hazards model assumption is that average reduction in hazard applies over the entire 20-year period. The P values shown are from multivariate models for given ER status. The ER status by chemotherapy interaction P value for disease-free survival is .02 and for overall survival is .05.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Berry DA, Cirrincione C, Henderson IC, et al. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA. 2006;295(14):1658–1667. doi:10.1001/jama.295.14.1658
Author Affiliations: University of Texas M. D. Anderson Cancer Center, Houston (Dr Berry); Cancer and Leukemia Group B Statistical Center, Durham, NC (Ms Cirrincione); University of California at San Francisco (Dr Henderson); Albert Einstein College of Medicine, Lake Success, NY (Dr Citron); North Shore University Hospital, Manhasset, NY (Dr Budman); Fox Chase Cancer Center, Philadelphia, Pa (Dr Goldstein); Angeles Clinic and Research Institute, Santa Monica, Calif (Dr Martino); Mayo Clinic and Mayo Foundation, Jacksonville, Fla (Dr Perez); Vermont Cancer Center, Burlington (Dr Muss); Memorial Sloan-Kettering Cancer Center, New York, NY (Drs Norton and Hudis); and the Dana-Farber Cancer Institute, Boston, Mass (Dr Winer).
Context Breast cancer estrogen-receptor (ER) status is useful in predicting benefit from endocrine therapy. It may also help predict which patients benefit from advances in adjuvant chemotherapy.
Objective To compare differences in benefits from adjuvant chemotherapy achieved by patients with ER-negative vs ER-positive tumors.
Design, Setting, and Patients Trial data from the Cancer and Leukemia Group B and US Breast Cancer Intergroup analyzed; patient outcomes by ER status compared using hazards over time and multivariate models. Randomized trials comparing (1): 3 regimens of cyclophosphamide, doxorubicin, and fluorouracil (January 1985 to April 1991); (2) 3 doses of doxorubicin concurrent with cyclophosphamide, with or without subsequent paclitaxel (May 1994 to April 1997); (3) sequential doxorubicin, paclitaxel, and cyclophosphamide with concurrent doxorubicin and cyclophosphamide followed by paclitaxel, and also 3-week vs 2-week cycles (September 1997 to March 1999). A total of 6644 node-positive breast cancer patients received adjuvant treatment.
Main Outcome Measures Disease-free and overall survival.
Results For ER-negative tumors, chemotherapy improvements reduced the relative risk of recurrence by 21%, 25%, and 23% in the 3 studies, respectively, and 55% comparing the lowest dose in the first study with biweekly cycles in the third study. Corresponding relative risk reductions for ER-positive tumors treated with tamoxifen were 9%, 12%, and 8% in the 3 studies, and 26% overall. The overall mortality rate reductions associated with chemotherapy improvements were 55% and 23% among ER-negative and ER-positive patients, respectively. All individual ER-negative comparisons and no ER-positive comparisons were statistically significant. Absolute benefits due to chemotherapy were greater for patients with ER-negative compared with ER-positive tumors: 22.8% more ER-negative patients survived to 5 years disease-free if receiving chemotherapy vs 7.0% for ER-positive patients; corresponding improvements for overall survival were 16.7% vs 4.0%.
Conclusion Among patients with node-positive tumors, ER-negative breast cancer, biweekly doxorubicin/cyclophosphamide plus paclitaxel lowers the rate of recurrence and death by more than 50% in comparison with low-dose cyclophosphamide, doxorubicin, and fluorouracil as used in the first study.
Great strides have been made in the treatment of early stage breast cancer. In patients with hormone-sensitive tumors, tamoxifen reduces the risk of recurrence and death by more than 30%.1 Moreover, treatment with aromatase inhibitors in place of or sequentially with tamoxifen further reduces the risk of recurrence in postmenopausal women with estrogen-receptor (ER)–positive tumors.2-4
In the absence of treatment, ER status is a weak prognostic factor, but it is a strong predictive factor in the sense that it identifies patients who may benefit from endocrine therapy. With appropriate endocrine therapy, patients with ER-positive disease have substantially better prognoses as a group than do those with ER-negative disease.
Evidence is accumulating that improvements in chemotherapy disproportionately benefit patients with ER-negative tumors. The most recent meta-analysis of randomized trials showed that for patients aged 50 to 69 years with ER-negative tumors and not receiving tamoxifen, the reduction in the risk of recurrence due to any kind of polychemotherapy was 33%; and for mortality it was 26%. For patients with ER-positive tumors receiving tamoxifen, the respective reductions were 15% and 11%.1 All 4 of the corresponding reductions for patients younger than age 50 years were between 32% and 39%.1 The apparent lack of an interaction between chemotherapy benefits and ER status in this younger age group may be due to the small sample size, but also could be related to the effect of chemotherapy on ovarian function in younger women.
The International Breast Cancer Study Group found that among patients with node-negative disease treated with tamoxifen, those with ER-negative tumors received substantial benefit from a 3-cycle regimen of cyclophosphamide, methotrexate, and fluorouracil, with a 48% reduction in the risk of recurrence and a 49% reduction in the risk of death from any cause. This substantial benefit is in sharp contrast to those patients with ER-positive tumors for whom both risks were reduced by only 1%.5 The neoadjuvant setting provides further supportive evidence: tumors without hormone receptors are more sensitive to chemotherapy than are hormone-sensitive tumors, with markedly higher rates of pathological complete response.6-8
In a retrospective subset analysis, we addressed whether node-positive breast cancer patients with ER-negative disease benefit more from recent improvements in adjuvant chemotherapy than do those with ER-positive tumors treated with tamoxifen. We compared disease-free and overall survival according to ER status among patients enrolled in 3 consecutive randomized trials of chemotherapy conducted by the Cancer and Leukemia Group B and the US Breast Cancer Intergroup (including the Eastern Cooperative Group, the Southwest Oncology Group, and the North Central Cancer Treatment Group).
The 3 consecutive studies (8541, 9344, and 9741) were coordinated by the Cancer and Leukemia Group B (studies 9344 and 9741 were Intergroup trials 0148 and C9741). The study protocols were approved by the institutional review boards of the participating centers, and all patients provided written informed consent. All 3 studies were randomized and addressed 1 or more questions related to the optimal use of chemotherapy in women with node-positive breast cancer. Women in all arms of the 3 trials received doxorubicin-based chemotherapy. Tamoxifen was not randomized in any of the studies but instead was recommended for certain patient subgroups based on the prevailing standard of care. Each study showed a benefit for at least 1 of the factors under investigation. For the present analysis, the results of all 3 studies were updated as of August 16, 2005.
Figure 1 shows the study designs, and Table 1 shows the clinical and tumor characteristics for the 3 studies. The studies were designed sequentially based on the earlier studies' results. In particular, the treatment group with the best results (or a slight variant thereof) in each of the first 3 studies served as the comparison group in the subsequent study.
Study 85419 involved the treatment of 1550 patients between January 1985 and April 1991. Patients were randomly assigned to 1 of 3 schedules of cyclophosphamide, doxorubicin (Adriamycin), and fluorouracil (CAF): high dose (600, 60, and 600 mg/m2, respectively, given in 4 cycles), moderate dose (400, 40, and 400 mg/m2 in 6 cycles), or low dose (300, 30, and 300 mg/m2 in 4 cycles). The high- and moderate-dose groups received the same total dose, and the low-dose group received half of that dose. Of patients with ER-positive tumors, 45% received tamoxifen (not randomized) after chemotherapy, and 68% of these patients were postmenopausal. Disease-free survival and overall survival were significantly increased in the moderate- and high-dose groups. The median follow-up at the time of our analysis was 17 years.
Study 934410 enrolled a total of 3121 patients who were treated between May 1994 and April 1997. In this 3×2 factorial study, patients were randomly assigned to doxorubicin at a dose of 60, 75, or 90 mg/m2, given concurrently with cyclophosphamide at a fixed dose of 600 mg/m2, with or without subsequent treatment with paclitaxel (175 mg/m2). Chemotherapy was given every 3 weeks for a total of 4 cycles. Of the patients with ER-positive tumors, 94% received tamoxifen at the completion of chemotherapy, as recommended by the protocol. Disease-free and overall survival were significantly increased in the group that received paclitaxel, but there was no evidence of a relationship between dose of doxorubicin and survival. At the time of our analysis, the median follow-up was 9 years.
Study 974111 involved the treatment of 1973 patients between September 1997 and March 1999. All patients received doxorubicin, cyclophosphamide, and paclitaxel at respective doses of 60, 600, and 175 mg/m2. The study had a 2×2 factorial design to assess 2 levels of dose density (2-week vs 3-week cycles) and 2 treatment sequences (concurrent administration of doxorubicin and cyclophosphamide followed by paclitaxel vs sequential administration of doxorubicin, paclitaxel, and cyclophosphamide). Of patients with ER-positive tumors, 91% received tamoxifen after chemotherapy. There was a significant improvement in disease-free and overall survival for the dose-dense group (2-week cycles) but no difference depending on treatment sequence. The median follow-up at the time of our analysis was 6 years.
Our primary objective was to assess the cumulative survival benefit of chemotherapy improvements over time according to ER status. We compared low-dose with high-dose CAF in study 8541, no paclitaxel with paclitaxel in study 9344, and 3-week with 2-week cycles in study 9741. We considered patients with ER-positive tumors only if they received tamoxifen.
We used Kaplan-Meier methods to determine survival according to ER status in each of the 3 studies. Events included in the analysis of disease-free survival were local, regional, and distant recurrences of breast cancer and deaths from any cause. Confidence intervals (CIs) for hazard ratios were based on Cox multivariate regression models comparing treatment groups, adjusted for menopausal status, number of positive axillary lymph nodes, and tumor size (with the square-root transformation used for the latter 2 variables, standard practice by the Cancer and Leukemia Group B).
In considering the cumulative effects of chemotherapy over the 3 studies, not all pairs of therapies have within-study comparisons. The process of comparing therapies across studies adds an extra level of variability.12-14 We addressed the comparability of similar treatments across consecutive studies using Cox models within ER categories: the high-dose CAF group in study 8541 with the no-paclitaxel group in study 9344, and the paclitaxel group in study 9344 with the group treated every 3 weeks in study 9741. The cumulative hazard ratio of improvements in chemotherapy (from low-dose CAF in study 8541 to the every-2-week regimens in study 9741) was calculated as the product of the hazard ratios from the individual studies. To address statistical significance of the differences in chemotherapy effects for the ER-positive and ER-negative subsets, we incorporated a chemotherapy/ER interaction factor in Cox proportional hazards modeling; for the totality of the 3 studies we also included study as a factor. We estimated the risks of recurrence over time according to ER status and compared these risks to determine which patients benefited from chemotherapy and when these benefits occurred. All analyses were conducted using JMP statistical software version 22.214.171.124 (SAS Institute Inc, Cary, NC); P<.05 was considered significant.
Disease-free and overall survival did not differ significantly between the group that received high-dose CAF in study 8541 and the group that received doxorubicin and cyclophosphamide without paclitaxel in study 9344, after adjustment for covariates, including ER status. Similarly, there were no significant differences in survival between the group that received doxorubicin and cyclophosphamide followed by paclitaxel in study 9344 and the groups given chemotherapy every 3 weeks in study 9741.
Figure 2 shows the results of multivariate Cox models for disease-free survival according to ER status. Overall, about 60% of the patients had ER-positive tumors. The ability to detect treatment differences was slightly greater in the ER-positive group because that group experienced 1472 events as opposed to 1152 in the ER-negative group. In each of the 3 studies, the differences in outcome by treatment were statistically significant among ER-negative patients but not among ER-positive patients who received tamoxifen (Table 2)—however, the ER-positive group still had numerically lower risks of recurrence and death with the more intensive treatment.
The every-2-week regimens of study 9741, as compared with low-dose CAF in study 8541, resulted in a 55% reduction in the risk of a recurrence among ER-negative patients (95% CI, 37% to 68%); the risk reduction was 26% (95% CI, –4% to 48%) for ER-positive patients. The respective overall reductions in the risk of death were 55% (95% CI, 38% to 69%) and 23% (95% CI, –17% to 49%).
The pattern of risks over time for ER-negative patients was similar across the 3 studies, with a high risk of an event in the first 2 to 3 years after treatment (Figure 3). The risks for ER-positive patients were also similar across the studies, but in contrast to the pattern for ER-negative patients, the risk of an event in the first few years was very low. A comparison of risks among ER-positive patients in study 8541 who received tamoxifen and those who did not (Figure 4) suggests that this low early risk was due to tamoxifen and not to the patients' ER status. The risks for ER-positive patients who did not receive tamoxifen were similar to those for ER-negative patients, with the former group experiencing a reduction of 67% in year 1 for high-dose CAF as compared with low-dose CAF.
From the standpoint of the patient, absolute benefit associated with a treatment program is far more important than the relative risk reduction. The ER-negative group experienced substantially greater absolute improvements in disease-free and overall survival rates. Figure 5 compares disease-free survival and overall survival for patients in the low-dose regimen of CAF in study 8541 with the same patients modeled as receiving biweekly doxorubicin and cyclophosphamide followed by paclitaxel as in study 9741. For ER-negative disease, the improvement was 22.8% at 5 years (Table 2) and 25.8% at 10 years. The corresponding improvements for ER-positive disease treated with tamoxifen were 7% at 5 years and 10% at 10 years.
Advances in the treatment of primary breast cancer include the use of chemotherapy, tamoxifen, and more recently, aromatase inhibitors for patients with ER-positive tumors, as well as trastuzumab for those with human epidermal growth factor receptor 2 (HER2)–positive disease.15-18 Breast cancer is heterogeneous, with differences among subtypes in treatment responses and outcomes. Patients with ER-positive tumors who receive adjuvant hormonal therapy have better disease-free and overall survival than do those with ER-negative tumors, particularly during the first 5 years after diagnosis. Our results indicate that advances in chemotherapy have lessened the survival differences between ER-positive patients who receive hormonal therapy and ER-negative patients, with the latter group deriving much greater benefit from modern improvements in chemotherapy regimens.
Since early and overall event rates are higher for patients with ER-negative tumor status than for those with ER-positive status, relative reductions in these rates due to improvements in chemotherapy translate into even greater absolute benefits for patients with ER-negative tumors. The absolute improvement in 5-year disease-free survival was 22.8% for ER-negative patients, as compared with 7.0% for ER-positive patients, and the difference for overall survival was also pronounced: an improvement of 16.7% for ER-negative patients vs 4.0% for ER-positive patients (Table 2 and Figure 3).
The risks of recurrence and death vary over time, as shown in Figure 4, and so do the reductions in risk that are attributable to improved chemotherapy. The high risk of an event in the first 2 to 3 years after treatment for ER-negative patients coincides with the period of time when the benefit of the more effective chemotherapy regimens is manifest. For example, the reduction in risk with high-dose CAF as compared with low-dose CAF was 55% in the first year and 30% in the second year. There was little or no advantage of high-dose CAF for ER-negative patients after 3 years. However, the benefit was durable in that there was no sign of a rebound in risk in the high-dose group in later years, a finding reflected as well by the persistent separation in the corresponding survival curves in Figure 2.
The benefit of chemotherapy in women with ER-positive tumors is far less dramatic, possibly because the benefits of improved adjuvant chemotherapy are due mostly, if not entirely, to a reduction in the risk of recurrence in the first few years after treatment. In this early period, the risk of recurrence is so small in ER-positive patients who are treated with tamoxifen, and presumably if they were treated with other hormonal therapies, that any additional risk reduction due to chemotherapy would be very difficult to detect statistically. Moreover, based on data from the preoperative setting, there is reason to believe that many ER-positive tumors are intrinsically less responsive to short courses of chemotherapy than ER-negative tumors. Despite the lack of a statistically significant benefit from improved chemotherapy regimens in ER-positive patients, some of these patients almost certainly derive an added benefit from such regimens. Identifying such patients is complex. In study 8541, HER2/neu overexpression or amplification identified patients who derived a benefit from high-dose CAF (600, 60, and 600 mg/m2, respectively, per cycle), which is now the standard CAF regimen.19,20 This benefit was independent of ER status (results not shown). Subgroup analyses according to HER2 status from studies 9344 and 9741 are pending. Although the findings will be of interest, they will have to be interpreted in light of recent data demonstrating a benefit of adjuvant and neoadjuvant trastuzumab therapy in patients with HER2-positive tumors.15-18,21-24 Of interest, recent studies have documented the benefits of chemotherapy in subsets of tamoxifen-treated patients who have hormone-responsive tumors,25,26 but they have also suggested that patients with ER-positive tumors who are not in these subsets derive little or no benefit from adjuvant chemotherapy.
No method of assessing ER status is perfect, and some tumors labeled ER-positive may actually be ER-negative.27 On a related note, an obvious question is whether the benefits of chemotherapy depend on the degree of ER positivity. Unfortunately, quantitative ER measurements were not routinely collected in our studies.
As Figure 4 illustrates, the risk of recurrence in both ER groups was between 2% and 4% per year after approximately 3 to 5 years and did not appear to be influenced by treatment. This level of risk is similar to that for women with node-negative disease. Moreover, the risk of recurrence decreased dramatically after about year 3, irrespective of the number of positive nodes and tumor size (data not shown). Tumors that have not recurred are those that are less aggressive or are sensitive to therapy: in effect, nonrecurrence trumps baseline clinical characteristics.
The long-term hazards were slightly higher in the ER-positive group than in those with ER-negative disease (Figure 4). Possible explanations for this finding are the development of resistance to initial hormonal therapy, differences in the underlying biology of the disease, or both.28
The Oxford Overview1 suggested a possible role of age in any interaction between ER status and benefits of early polychemotherapy regimens, although the subset sample sizes were small. Our study also has a sample size limitation. However, we addressed this interaction and found little evidence that age plays a role. If anything, in our studies the interaction between ER status and chemotherapy benefits is stronger in younger women. In particular, for women younger than 50 years who had ER-positive tumors treated with tamoxifen, there was no suggestion of a benefit for the accumulation of more intensive and extensive chemotherapies over the 3 studies.
Our analysis has several limitations. One is that patients admitted to our clinical trials may not be typical of patients generally (although there is evidence from models of breast cancer that adjuvant therapy benefits observed in clinical trials applies as well to the general US population29). We combined the results of 3 trials with a total of 13 treatment regimens. The trials were randomized separately, and each patient was eligible to receive only a subgroup of the 13 regimens. Each trial was confounded with any covariates that were temporally related, limiting the ability to draw definitive conclusions based on cross-study analyses. For example, the use of screening mammography increased over the course of these studies. There is a well-understood stage shift for cancers detected on screening, but such cancers are also associated with an improved prognosis, even after accounting for known prognostic factors.30,31 We accounted for known patient and tumor characteristics using multivariate analyses, but we did not have information about how the patients' cancers were detected.
Another limitation is that tamoxifen therapy was not randomly assigned in the studies we considered. In studies 9344 and 9741, almost all ER-positive patients received tamoxifen, and we compared ER-positive patients who received tamoxifen with ER-negative patients. In a separate analysis of study 8541, the benefit of more intensive chemotherapy was similar in ER-positive patients not treated with tamoxifen and in ER-negative patients. There may have been a bias in the assignment of tamoxifen in study 8541; however, with the exception of menopausal status, the most important determinant of tamoxifen use was time, with much greater use after the announcement of the Oxford Overview results in 1988.32
Multiple comparisons are a concern in any subgroup analysis; examining enough subgroups will identify spurious treatment correlations, with the effects tending to be stronger with greater numbers of subgroups examined.33,34 Subgroup analyses based on hypotheses established from previous trials are less problematic. In our study, the 3 trials independently show the same effect. Viewing one study as hypothesis-generating leaves the other 2 as confirmatory. The fact that the specific chemotherapy question differed across the 3 trials is an important consideration but may not be relevant. Our analysis suggests that the biological subtype of breast cancer is the most important predictor of the benefits of an improved chemotherapy regimen, regardless of the specific regimen.
Our study has 2 substantive clinical implications. First, although patients with ER-positive breast tumors may reasonably opt for chemotherapy, they should recognize that the benefits are not great as compared with those for patients with ER-negative disease. The benefits of intensive and extensive chemotherapy for unselected patients who have ER-positive disease treated with tamoxifen are modest at best. Whether such patients should opt for chemotherapy will depend on their attitudes toward the associated negative sequelae. In the years ahead, it is likely that we will have better predictors that will allow clinicians to determine which patients with ER-positive disease truly benefit from the addition of chemotherapy.25,26 Second, with advances in chemotherapy, patients with ER-negative tumors have had sequentially improved outcomes and their prognoses now approach those of optimally treated patients with ER-positive disease. For patients with ER-negative disease, the overall disease-free survival and overall survival benefits of modern intensive and extensive chemotherapy considered in our study are substantial.
Corresponding Author: Donald A. Berry, PhD, Department of Biostatistics and Applied Mathematics, University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Unit 447, Houston, TX 77030-4009 (email@example.com).
Author Contributions: Dr Berry had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Berry, Henderson, Citron, Goldstein, Martino, Norton, Hudis, Winer.
Acquisition of data: Cirrincione, Henderson, Citron, Budman, Goldstein, Martino, Perez, Muss, Norton, Hudis.
Analysis and interpretation of data: Berry, Cirrincione, Henderson, Citron, Martino, Muss, Norton, Hudis, Winer.
Drafting of the manuscript: Berry, Budman, Perez, Muss, Hudis, Winer.
Critical revision of the manuscript for important intellectual content: Berry, Cirrincione, Henderson, Citron, Budman, Goldstein, Martino, Muss, Norton, Hudis, Winer.
Statistical analysis: Berry, Cirrincione.
Obtained funding: Henderson, Muss, Hudis, Winer.
Administrative, technical, or material support: Cirrincione, Henderson, Citron, Budman, Goldstein, Muss, Norton, Hudis, Winer.
Study supervision: Berry, Henderson, Citron, Budman, Norton, Hudis, Winer.
Financial Disclosures: Dr Berry provides consultancies to Bristol-Myers Squibb, Eli Lilly, and Novartis and receives honoraria from AstraZeneca and Pfizer. Dr Citron consults for Amgen and Genentech and receives honoraria from Amgen, Genentech, and AstraZeneca. Dr Goldstein consults for and receives honoraria from Bristol-Myers Squibb. Dr Hudis consults for, provides research support for, and receives honoraria from AstraZeneca, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, and Sanofi-Aventis and holds stock ownership with Genomic Health. Dr Winer serves on an advisory board for Bristol-Myers Squibb.
Funding/Support: This study was supported in part by a grant (CA31946) from the National Cancer Institute to the Cancer and Leukemia Group B.
Role of the Sponsor: The funder had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.
This article was corrected on 4/19/06, prior to publication of the correction in print.